Pulmonx Corporation (LUNG)

Etorro trading 970x250
Pulmonx Corporation (LUNG) Logo

About Pulmonx Corporation

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. Address: 700 Chesapeake Drive, Redwood City, CA, United States, 94063

Pulmonx Corporation News and around…

Latest news about Pulmonx Corporation (LUNG) common stock and company :

Is Pulmonx Corporation (LUNG) A Good Stock To Buy?
27 Oct, 2021 Yahoo! Finance

A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021
26 Oct, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Tuesday, November 2, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by

Can Pulmonx Corporation (LUNG) Climb 43% to Reach the Level Wall Street Analysts Expect?
20 Oct, 2021 Yahoo! Finance

The consensus price target hints at a 42.8% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Implied XHE Analyst Target Price: $152
04 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $152.35 per unit.

Chief Financial Officer Of Pulmonx Makes $224.56 Thousand Sale
22 Sep, 2021 FinancialContent

Derrick Sung, Chief Financial Officer at Pulmonx (NASDAQ:LUNG), made a large insider sell on September 21, according to a new SEC ...

Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment
21 Sep, 2021 FinancialContent

Pulmonx Announces BCBS of Michigan and Horizon BCBS of New Jersey Issue Coverage Policies Providing Coverage for Treatment with the Zephyr® Valve

President And CEO Of Pulmonx Sold $1.85 Million In Stock
21 Sep, 2021 Yahoo! Finance

Glendon E. French, President And CEO at Pulmonx (NASDAQ:LUNG), made a large insider sell on September 20, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that French sold 48,571 shares of Pulmonx at prices ranging from $37.31 to $38.86. The total transaction amounted to $1,852,124. Following the transaction, French no longer owns shares of the company. Pulmonx shares are trading up 0.99% at $37.67 at the time of this

3 Healthcare Stocks That Might Skyrocket When COVID Is Over
07 Sep, 2021 FinancialContent

Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?

Pulmonx to Present at Upcoming September Investor Conferences
26 Aug, 2021 FinancialContent
Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment
20 Aug, 2021 FinancialContent

Positive Coverage Policy Gives Additional 34 Million People Access to Treatment with the Zephyr® Valve, a Minimally Invasive Treatment Option

Return on Capital Employed Overview: Pulmonx
20 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Pulmonx (NASDAQ:LUNG) brought in sales totaling $12.20 million. However, ...

Pulmonx Corporation (LUNG) Q2 2021 Earnings Call Transcript
04 Aug, 2021 FinancialContent

LUNG earnings call for the period ending June 30, 2021.

Pulmonx Reports Second Quarter 2021 Financial Results
03 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
03 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Healthcare Delivery Networks
02 Aug, 2021 FinancialContent

Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

Analysts Forecast 16% Gains Ahead For XHE
30 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $150.02 per unit.

Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference
29 Jul, 2021 FinancialContent
Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema
27 Jul, 2021 FinancialContent

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long-term follow-up data of the IMPACT Study, a multi-center randomized clinical trial of the Zephyr® Valves. The IMPACT data show that Zephyr Valves deliver significant benefits to a group of severe COPD/emphysema patients that have very few treatment options because of widespread destruction of lung tissue across their lungs (also known as homogenous distribution of emphysema). The Zephyr Valve is the only endobronchial valve to receive approval from the FDA for treatment of patients with homogenous distribution of the disease, making it the only minimally invasive option to help these patients breathe easier once medications no longer control disease symptoms.

3 Small-Cap Healthcare Stocks Worth a Look
20 Jul, 2021 FinancialContent

Some stocks with great potential.

Pulmonx to Report Second Quarter 2021 Financial Results on August 3, 2021
20 Jul, 2021 FinancialContent
Have Insiders Been Buying Pulmonx Corporation (NASDAQ:LUNG) Shares?
19 Jul, 2021 Yahoo! Finance

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

Pulmonx is Now Oversold (LUNG)
15 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Is Pulmonx Corporation (LUNG) A Good Stock To Buy Now?
13 Jul, 2021 Yahoo! Finance

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the fourth quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]

Wednesday 6/30 Insider Buying Report: WPF, LUNG
30 Jun, 2021 FinancialContent

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

Analysts See 15% Gains Ahead For The Holdings of XHE
24 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $147.73 per unit.

Analysts Expect XHE Will Reach $145
21 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $144.85 per unit.

Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/Emphysema
17 May, 2021 FinancialContent

New Data Presented at ATS 2021 International Conference Shows Positive, Sustained Benefits to Patients Treated with this First Minimally Invasive, Non-drug Treatment Option

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
14 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Pulmonx Corporation (NASDAQ:LUNG) Released Earnings Last Week And Analysts Lifted Their Price Target To US$60.14
07 May, 2021 Yahoo! Finance

Pulmonx Corporation ( NASDAQ:LUNG ) defied analyst predictions to release its first-quarter results, which were ahead...

Pulmonx Corporation (LUNG) is a NASDAQ Common Stock listed in ,

970x250